GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » YoY EPS Growth

Liquidia (FRA:LT4) YoY EPS Growth : -20.00% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Liquidia YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Liquidia's YoY EPS Growth for the quarter that ended in Sep. 2024 was -20.00%.

Liquidia's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €-0.27.

Liquidia YoY EPS Growth Historical Data

The historical data trend for Liquidia's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia YoY EPS Growth Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial 64.96 37.44 57.15 -1.94 -75.63

Liquidia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.57 -352.94 -195.83 -3.61 -20.00

Liquidia YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Liquidia's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.11--0.632)/ | -0.632 |
=-75.63 %

Liquidia's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Sep. 2023 )) / | Earnings per Share (Diluted) (Q: Sep. 2023 )) |
=(-0.27--0.225)/ | -0.225 |
=-20.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liquidia YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Liquidia's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » YoY EPS Growth
Comparable Companies
BCAX ZYME BCYC REPL AVXL VIR UPB NUVB ADPT ETNB VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
LQDA:USA LT4:Germany
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Website
https://www.liquidia.com
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines